1. ALLA AKTIER
  2. NYHETER
  3. NEWBURY PHARMACEUTICALS

Newbury Pharmaceuticals

Nyheter Newbury Pharmaceuticals Nyheter alla bolag

Solifenacin/Tamsulosin Newbury approved by the Norwegian Health Authorities

Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Solifenacin/Tamsulosin Newbury 6 mg/0,4 mg modified release tablets in Norway as the first country in a dual country registration procedure. Approval in Denmark is expected to follow upon finalized national review.

“The product is a fully bioequivalent version of Urizia MR Tablets, 6mg/0,4mg. Urizia is a niche product, indicated for the treatment of urinary tract symptoms associated with Benign Prostatic Hyperplasia (BPH) in men, who are not adequately responding to treatment with monotherapy. Based on this positive progress, we will proceed to launch this product, within the respective markets as soon as regulatory exclusivities and patents allow us.” Says Mr. Lars Minor, CEO of Newbury.

Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate gland. Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control.

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

Solifenacin/Tamsulosin Newbury approved by the Norwegian Health Authorities

Datum 2023-05-02, kl 11:00
Källa MFN
Bifogade filer
Solifenacin/Tamsulosin Newbury approved by the Norwegian Health Authorities
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!